In TNBC, tumor cells compete for glutamine in the TME, leading to an inhibited antitumor immune response by tumor-infiltrating T lymphocytes, and in a GLS-deficient mouse model, limiting glutamine access to tumor cells restored tumor-infiltrating T lymphocyte activity (8). Here, GLS is linked to neoplasm.